The ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe was published in Annals of Oncology in September 2017.
- To provide national health authorities with data on the availability of licensed anti-neoplastic medicines across Europe so that they can decide how to best resolve the challenges identified
- To report on the actual availability of anti-neoplastic medicines to patients when they are prescribed and when patients can afford them
- To map the international situation, particularly in view of recent medicines shortages of some common, affordable, medically necessary anti-cancer medicines
The ESMO study mapped the international variation on the out-of-pocket costs and availability of cancer medicines in particularly in view of recent medicines shortages of some common, affordable, medically necessary anti-cancer medicines, including those on the WHO Model List of Essential Medicines. In addition, it revealed that limited national resources pose a formidable barrier to expensive, innovative medicines which can provide gains in non-curative settings.
Find out about the international presentations of this study here.
This ESMO study was conducted under the auspices of the ESMO Global Policy Committee in collaboration with the:
- World Health Organization (WHO)
- European Society of Oncology Pharmacy (ESOP) - liaising with the International Society of Oncology Pharmacy Practitioners (ISOPP)
- Kings College London Institute of Cancer Policy
- Union for International Cancer Control (UICC)
- American Society of Clinical Oncology (ASCO)
- Chinese Society of Clinical Oncology (CSCO)
- Indian Society for Medical & Pediatric Oncology (ISMPO)
- Japanese Society of Medical Oncology (JSMO)
- Korean Society of Medical Oncology (KSMO)
- Myanmar Oncology Society (MOS)
- Medical Oncology Group of Australia Incorporated (MOGA)
- Medical Oncology Society of Peru (SPOM - Sociedad Peruana de Oncologia Médica)
- Middle East Cancer Consortium (MECC)